Differentiation of glioblastoma and primary CNS lymphomas using susceptibility weighted imaging

• Verfasst von: Radbruch, Alexander [VerfasserIn]
• Verfasst von: Wiestler, Benedikt [VerfasserIn]
• Verfasst von: Kramp, Linda Katharina [VerfasserIn]
• Verfasst von: Lutz, Kira [VerfasserIn]
• Verfasst von: Bäumer, Philipp [VerfasserIn]
• Verfasst von: Weiler, Markus [VerfasserIn]
• Verfasst von: Röthke, Matthias C. [VerfasserIn]
• Verfasst von: Sahm, Felix [VerfasserIn]
• Verfasst von: Schlemmer, Heinz-Peter [VerfasserIn]
• Verfasst von: Wick, Wolfgang [VerfasserIn]
• Verfasst von: Heiland, Sabine [VerfasserIn]
• Verfasst von: Bendszus, Martin [VerfasserIn]
• Titel: Differentiation of glioblastoma and primary CNS lymphomas using susceptibility weighted imaging
• Verf.angabe: Alexander Radbruch, Benedikt Wiestler, Linda Kramp, Kira Lutz, Philipp Bäumer, Markus Weiler, Matthias Roethke, Felix Sahm, Heinz-Peter Schlemmer, Wolfgang Wick, Sabine Heiland, Martin Bendszus
• E-Jahr: 2013
• Jahr: March 2013
• Umfang: 5 S.
• Fussnoten: Published online: December 12, 2012 ; Gesehen am 28.11.2018
• Titel Quelle: Enthalten in: European journal of radiology
• Ort Quelle: Amsterdam [u.a.] : Elsevier Science, 1990
• Jahr Quelle: 2013
• Band/Heft Quelle: 82(2013), 3, Seite 552-556
• ISSN Quelle: 1872-7727
• DOI: doi:10.1016/j.ejrad.2012.11.002
• Datenträger: Online-Ressource
• Sprache: eng
• Sach-SW: FLAIR
• Sach-SW: fluid attenuated inversion recovery
• Sach-SW: Glioblastoma
• Sach-SW: intratumoural susceptibility signals
• Sach-SW: Intratumoural susceptibility signals
• Sach-SW: ITSS
• Sach-SW: PCNSL
• Sach-SW: primary central nervous system lymphoma
• Sach-SW: Primary CNS lymphoma
• Sach-SW: Susceptibility weighted imaging
• K10plus-PPN: 1584606959

Abstract

Introduction Reliable differentiation between glioblastoma and primary CNS lymphoma (PCNSL) using conventional MR imaging is challenging, since both entities may show similar appearance on structural MR imaging. Here we analyzed if the appearance of intratumoural susceptibility signals (ITSS) on susceptibility weighted imaging (SWI) may differentiate between both entities. Methods and materials SWI and contrast enhanced T1-weighted images were acquired from 15 patients with newly diagnosed PCNSL (14 B-cell PCNSL, 1 T-cell PCNSL) and 117 patients with newly diagnosed glioblastoma with a 3 Tesla MR. Additional phase images were available in 8 patients with PCNSL and 88 patients with glioblastoma. Appearance of ITSS was assessed by two readers on SWI and the size of the enhancing lesions on contrast enhanced T1-weighted images were measured. Furthermore it was assessed if ITSS displayed more clearly on SWI or on phase images. Results ITSS were detected in 106 (reader 1) and 109 (reader 2) glioblastoma, respectively. Both readers identified ITSS within the T-cell PCNSL while both readers did not identify any ITSS within the 14 Bcell PCNSL. Interrarter variability as determined by Cohen κ was excellent for glioblastoma (κ = 0.938) and for PCNSL (κ = 1). The medium size of the enhancing lesion of the glioblastoma that did not harbour ITSS was significantly smaller than the size of the glioblastoma exhibiting ITSS (p < 0.008). All identified ITSS displayed more clearly on SWI than on phase images. Conclusion Presence of ITSS differentiates reliably between glioblastoma and B-cell PCNSL and provides a fast bases for the clinical decision without causing any postprocessing work.